Retrophin Inc (RTRX) : Amici Capital reduced its stake in Retrophin Inc by 30.51% during the most recent quarter end. The investment management company now holds a total of 638,030 shares of Retrophin Inc which is valued at $11,057,060 after selling 280,108 shares in Retrophin Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Retrophin Inc makes up approximately 2.25% of Amici Capital’s portfolio.
Other Hedge Funds, Including , Millennium Management reduced its stake in RTRX by selling 140,469 shares or 29.06% in the most recent quarter. The Hedge Fund company now holds 342,830 shares of RTRX which is valued at $5,941,244. Retrophin Inc makes up approx 0.01% of Millennium Management’s portfolio.Geode Capital Management boosted its stake in RTRX in the latest quarter, The investment management firm added 8,076 additional shares and now holds a total of 270,805 shares of Retrophin Inc which is valued at $4,693,051.Perceptive Advisors boosted its stake in RTRX in the latest quarter, The investment management firm added 280,000 additional shares and now holds a total of 3,279,380 shares of Retrophin Inc which is valued at $56,831,655. Retrophin Inc makes up approx 4.16% of Perceptive Advisors’s portfolio.Ubs Asset Management Americas Inc boosted its stake in RTRX in the latest quarter, The investment management firm added 8,100 additional shares and now holds a total of 19,500 shares of Retrophin Inc which is valued at $340,275. Princeton Alpha Management Lp sold out all of its stake in RTRX during the most recent quarter. The investment firm sold 10,374 shares of RTRX which is valued $196,172.
Retrophin Inc opened for trading at $16.09 and hit $16.75 on the upside on Thursday, eventually ending the session at $16.35, with a gain of 2.06% or 0.33 points. The heightened volatility saw the trading volume jump to 4,10,672 shares. Company has a market cap of $601 M.
On the company’s financial health, Retrophin Inc reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.11. The company had revenue of $33.30 million for the quarter, compared to analysts expectations of $32.69 million. The company’s revenue was up 38.2% compared to the same quarter last year.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.